1. Generics Bulletin

Alkem Looks To Biosimilars With Enzene’s Teriparatide In India

Rival To Eli Lilly’s Forteo Will Help Alkem Move Into Biosimilars

 
• By Dave Wallace

With the approval in India of its Enzene subsidiary’s version of teriparatide, Alkem is setting its sights on the biosimilars market.

India_Testing
Alkem’s Enzene has had its teriparatide approved in India • Source: Shutterstock

Alkem Laboratories says it is aiming to replicate its success in small-molecule generics with biosimilars, after announcing the approval in India of a rival to Eli Lilly’s Forteo (teriparatide) osteoporosis treatment. The approval came through Alkem’s Enzene Biosciences subsidiary.

Announcing the marketing authorization obtained from the Drug Controller General of India for teriparatide, Alkem said that “according to company sources the clinical trial conducted for Enzene's teriparatide is one of the most comprehensive trials for

More from Biosimilars

More from Products

Amneal Proud To Be ‘Made In America’ And Ready To Scale Up Its US Manufacturing

 
• By Urtė Fultinavičiūtė

Amneal has set itself apart from competitors who are scrambling to find alternatives if proposed US pharmaceutical tariffs come into place. For the New Jersey-based firm, this is an opportunity to embrace its American identity and open a new chapter of growth.

‘I’ll Be Happy When We Have 40-Plus Assets’ – Sandoz Builds Up Biosimilars

 
• By Dave Wallace

With biosimilars playing an increasingly important role in Sandoz’s business, the firm’s first-quarter results call saw management lay out the latest key developments. Meanwhile, the company also addressed the issue of US tariffs, voicing optimism over both future developments as well as its ability to weather current measures.

Tetris Deal Falls Into Place For UK’s Aspire

 
• By Dave Wallace

Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.